Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Cytomx Thera (CTMX)

8.155   0.105 (1.3%) 06-04 16:00
Open: 8.02 Pre. Close: 8.05
High: 8.6599 Low: 8.01
Volume: 745,431 Market Cap: 375M
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.668 - 8.71 8.71 - 8.746
Low: 7.915 - 7.961 7.961 - 8
Close: 8.081 - 8.152 8.152 - 8.214

Technical analysis

as of: 2020-06-04 4:30:07 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 14.61     One year: 18.02
Support: Support1: 7.78    Support2: 6.47
Resistance: Resistance1: 12.51    Resistance2: 15.43
Pivot: 8.86
Moving Average: MA(5): 8.25     MA(20): 10.15
MA(100): 8.13     MA(250): 8.36
MACD: MACD(12,26): -0.53     Signal(9): -0.22
Stochastic oscillator: %K(14,3): 6.21     %D(3): 4.42
RSI: RSI(14): 38.48
52-week: High: 15.43  Low: 3.60  Change(%): -21.5
Average Vol(K): 3-Month: 64845  10-Days: 72783

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
CTMX has closed above bottom band by 14.3%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to CTMX's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 08 May 2020
CytomX Therapeutics, Inc. (CTMX) Q1 2020 Earnings Call Transcript - Motley Fool

Thu, 21 May 2020
Pomerantz Law Firm Announces the Filing of a Class Action against CytomX Therapeutics Inc. and Certain Officers – CTMX - GlobeNewswire

Wed, 03 Jun 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX - Yahoo Finance

Mon, 18 May 2020
CytomX Slumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Wed, 03 Jun 2020
Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Conn's, Elanco Animal Health, Ryder System, and CytomX and Encourages Investors to Contact the Firm - GlobeNewswire

Fri, 29 May 2020
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 46
Shares Float (M) 37
% Held by Insiders 2.30
% Held by Institutions 84.32
Shares Short (K) 1,070
Shares Short P. Month (K) 864

Stock Financials

EPS -1.670
EPS Est This Year -1.490
EPS Est Next Year -1.410
Book Value (p.s.) 1.520
Profit Margin -97.82
Operating Margin -125.16
Return on Assets (ttm) -13.8
Return on Equity (ttm) -78.9
Qtrly Rev. Growth 68.2
Gross Profit (p.s.) 1.252
Sales Per Share 1.690
EBITDA (p.s.) -2.059
Qtrly Earnings Growth
Operating Cash Flow (M) -151
Levered Free Cash Flow (M) -177

Stock Valuations

PE Ratio -4.88
PEG Ratio
Price to Book value 5.37
Price to Sales 4.82
Price to Cash Flow -2.48

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.